LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
On February 25, 2020, Lipocine Inc. (the “Company” or “Lipocine”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”). to the terms of the Placement Agency Agreement, the Placement Agent has agreed to use its reasonable best efforts to arrange for the sale of an aggregate of 10,084,034 Class A Units (the “Class A Units”), each consisting of one share of common stock, $0.0001 par value per share (the “Shares”) and one warrant (the “Common Warrants”) to purchase one-half of a share of the Company’s common stock. The Company will pay to the Placement Agent a cash fee equal to 5.5% of the gross proceeds generated from the sale of the Class A Units.
The Common Warrants to be issued in the offering will be exercisable beginning on the closing date and expire on the fifth anniversary of the closing date and have an initial exercise price equal to $0.53 per share, subject to adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s Common Stock.
The Placement Agency Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination provisions. The Company intends to use the net proceeds from the sale of the Units for working capital and general corporate purposes.
Also on February 25, 2020, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional purchasers of the Units. The Purchase Agreement provides for the sale and issuance by the Company of an aggregate of 10,084,034 Class A Units at an offering price of $0.595 per Class A Unit, for gross proceeds of approximately $6 million before deducting the Placement Agent’s fees and related offering expenses. The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination provisions.
Under the Purchase Agreement, the Company has agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of the Company’s common stock or common stock equivalents from February 25, 2020 until April 27, 2020 (the “Restricted Period”), other than certain exempt issuances including, but not limited to, securities issued to the Company’s equity compensation plans. The officers and directors of the Company have also agreed, to individual lock-up agreements, not to sell, hypothecate, pledge or otherwise dispose of any shares of the Company’s common stock or any security convertible, exchangeable or exercisable into, shares of common stock of the Company during the Restricted Period.
In addition, each institutional investor who entered into the Purchase Agreement has entered into a Leak-Out Agreement with the Company (each, a "Leak-Out Agreement" and collectively, the "Leak-Out Agreements") wherein each investor who is party to a Leak-Out Agreement (together with certain of its affiliates) has agreed to not sell, dispose or otherwise transfer, directly or indirectly (including, without limitation, any sales, short sales, swaps or any derivative transactions that would be equivalent to any sales or short positions), on any trading day from the public announcement of the Offering and ending at 4:00 pm (New York City time) on March 10, 2020, shares of Common Stock, or shares of Common Stock underlying any Common Stock equivalents held by such investor on the date of the Leak-Out Agreements, including the Warrant Shares, in an amount more than its pro rata portion of 25% of the trading volume of the Common Stock (increasing to 35% for sales by the holder at a price per share between $0.60 and $0.70), subject to certain exceptions. This restriction will not apply to any actual "long" (as defined in Regulation SHO promulgated under the Securities Exchange Act of 1934, as amended) sales by such investor (together with certain of its affiliates) at a price per share greater than $0.70 or to any long sales of shares of Common Stock purchased in open market transactions by such investor (together with certain of its affiliates) during the restricted period. Further, this restriction will not apply to sales or transfers of any such shares of Common Stock in transactions which do not need to be reported on the Nasdaq consolidated tape so long as the purchaser or transferee executes and delivers a Leak-Out Agreement. After such sale or transfer, future sales of the securities covered by the Leak-Out Agreement by the original owner (together with certain of its affiliates) and the purchaser or transferee will be aggregated to determine compliance with the terms of the Leak-Out Agreements.
The securities are being offered and sold to the Company’s effective registration statement (the “Registration Statement”) on Form S-3 (Registration No. 333-220942), which was declared effective by the Securities Exchange Commission (the “SEC”) on November 21, 2017, and the base prospectus included therein, as amended and supplemented by the prospectus supplement filed with the SEC on February 26, 2020. The offering is expected to close on or about February 27, 2020, subject to satisfaction of customary closing conditions.
The Placement Agency Agreement and Purchase Agreement are filed as Exhibits 10.1, and 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The form of the Common Warrant is attached as Exhibit 4.1 to this Current Report on Form 8-K and are incorporated herein by reference. The foregoing descriptions of the Placement Agency Agreement, Purchase Agreement, and Common Warrants do not purport to be complete and are qualified in their entirety by reference to such exhibits.
The Placement Agency Agreement and Purchase Agreement are attached hereto as exhibits to provide interested persons with information regarding the sale of the Shares, but are not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Placement Agency Agreement and Purchase Agreement were made only for purposes of such agreement and as of specific dates; were solely for the benefit of the parties thereto; and may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made by each contracting party to the other for the purposes of allocating contractual risk between them that differ from those applicable to investors. Investors should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries, affiliates, businesses or stockholders. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Placement Agency Agreement and Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures or statements by the Company. Accordingly, investors should read the representations and warranties in the Placement Agency Agreement and Purchase Agreement not in isolation but only in conjunction with the other information about the Company included in reports, statements and other filings made with the SEC.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements that are made to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company’s anticipated offering of the Units. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties, many of which are beyond our control, that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include the ability of the Company to satisfy certain conditions to closing the offering on a timely basis or at all, the uncertain amount of funds to be raised from the offering, the terms of the securities sold in the offering, as well as other risks described in the section entitled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed with the SEC on March 6, 2019 and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Item 8.01 Other Events.
In connection with the offering, the Company is filing a legal opinion and consent as Exhibit 5.1 and Exhibit 23.1 to this report, which are incorporated by reference into the Registration Statement.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description |
| 4.1 | Form of Warrant |
| 5.1 | Opinion of Dorsey & Whitney LLP |
| 10.1 | Placement Agency Agreement, dated as of February 25, 2020, by and between Lipocine, Inc. and Roth Capital Partners, LLC |
| 10.2 | Securities Purchase Agreement, dated as of February 25, 2020, by and between Lipocine, Inc. and the purchasers identified on the pages thereto |
| 23.1 | Consent of Dorsey & Whitney LLP (include in Exhibit 5.1) |
Lipocine Inc. Exhibit
EX-4.1 2 tm209716d3_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT lipocine inc. Warrant Shares: _______ Initial Exercise Date: February __,…
To view the full exhibit click here
About LIPOCINE INC. (NASDAQ:LPCN)
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
